Tofacitinib Treatment in Primary Herpes Simplex Encephalitis Interferes With Antiviral Response

Tofacitinib, a Janus kinase inhibitor, is a novel immunosuppressive drug for treatment of rheumatoid arthritis. Herpes simplex virus type 1 (HSV-1) may cause encephalitis during primary infection or following reactivation from a latent state. Long-term tofacitinib treatment may increase the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzyzowska, Malgorzata, Jarneborn, Anders, Thorn, Karolina, Eriksson, Kristina, Jin, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635063/
https://www.ncbi.nlm.nih.gov/pubmed/35217873
http://dx.doi.org/10.1093/infdis/jiac040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635063/
https://www.ncbi.nlm.nih.gov/pubmed/35217873
http://dx.doi.org/10.1093/infdis/jiac040

Ejemplares similares